Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer

6 Aug 2021

Abstract excerpt

PURPOSE: Up to 20% of patients with biliary tract cancer (BTC) have alterations in DNA damage response (DDR) genes, including homologous recombination (HR) genes. Therefore, the DDR pathway could be a promising target for new drug development in BTC. We aim to investigate the anti-tumor effects using poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors in BTC. MATERIALS AND METHODS: We used 10 BTC cell lines to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34352995
DOI: 10.4143/crt.2021.473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract CancerPMID 34352995Read ↗

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studiesSemantic proximity Read ↗

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?Semantic proximity Read ↗

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpointSemantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancerSemantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Semantic proximity Read ↗

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancerSemantic proximity Read ↗

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute LeukemiaSemantic proximity Read ↗

Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitorsSemantic proximity Read ↗

LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.